CAMBRIDGE, Mass., Sept. 10,
2024 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced its participation in the following
upcoming virtual investor conferences:
- Stifel 2024 Immunology and Inflammation Virtual Summit on
Tuesday, September 17, 2024, at
2:00 p.m. ET.
- TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.
A live webcast of each presentation will be available by
visiting the Investors & Media section of Blueprint Medicines'
website at http://ir.blueprintmedicines.com. A replay of the
webcasts will be archived on Blueprint Medicines' website for 30
days following each presentation.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated
biopharmaceutical company that invents life-changing medicines. We
seek to alleviate human suffering by solving important medical
problems in two core focus areas: allergy/inflammation and
oncology/hematology. Our approach begins by targeting the root
causes of disease, using deep scientific knowledge in our core
focus areas and drug discovery expertise across multiple
therapeutic modalities. We have a track record of success with two
approved medicines, including
AYVAKIT®/AYVAKYT® (avapritinib) which we are
bringing to patients with systemic mastocytosis (SM) in the U.S.
and Europe. Leveraging our
established research, development, and commercial capability and
infrastructure, we now aim to significantly scale our impact by
advancing a broad pipeline of programs ranging from early science
to advanced clinical trials in mast cell diseases including SM and
chronic urticaria, breast cancer and other solid tumors. For more
information, visit www.BlueprintMedicines.com and follow us on X
(formerly Twitter; @BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-302232128.html
SOURCE Blueprint Medicines Corporation
